Emerging monitoring technologies in kidney transplantation

Ehlayel, Abdulla M.; Simms, K'joy J A; Ashoor, Isa

doi:10.1007/s00467-021-04929-9

Cited by 5 publications

(5 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Non-invasive technologies to monitor kidney allograft health utilizing high-throughput assays of blood and urine specimens are emerging out of the research realm and slowly becoming part of everyday clinical practice [ 45 ]. The need for biomarkers in kidney transplantation stems from various observations [ 46 ].…”

Section: Metabolomics In Kidney Transplantationmentioning

confidence: 99%

New Insights from Metabolomics in Pediatric Renal Diseases

Riccio¹,

Valentino²,

Passaro³

et al. 2022

Children

View full text Add to dashboard Cite

Renal diseases in childhood form a spectrum of different conditions with potential long-term consequences. Given that, a great effort has been made by researchers to identify candidate biomarkers that are able to influence diagnosis and prognosis, in particular by using omics techniques (e.g., metabolomics, lipidomics, genomics, and transcriptomics). Over the past decades, metabolomics has added a promising number of ‘new’ biomarkers to the ‘old’ group through better physiopathological knowledge, paving the way for insightful perspectives on the management of different renal diseases. We aimed to summarize the most recent omics evidence in the main renal pediatric diseases (including acute renal injury, kidney transplantation, chronic kidney disease, renal dysplasia, vesicoureteral reflux, and lithiasis) in this narrative review.

show abstract

Section: Metabolomics In Kidney Transplantationmentioning

confidence: 99%

New Insights from Metabolomics in Pediatric Renal Diseases

Riccio¹,

Valentino²,

Passaro³

et al. 2022

Children

View full text Add to dashboard Cite

show abstract

“…Повышение выживаемости и качества жизни реципиентов трансплантата во многом будет зависеть от исследований, направленных на повышение толерантности с целью достижения состояния без иммуносупрессии после трансплантации. По данным литературы последних лет, применение аутологичных мезенхимальных стволовых клеток костного мозга реципиентам трансплантата почки привело к снижению частоты острого отторжения, уменьшению оппортунистических инфекций и улучшению почечной функции по сравнению с терапией индукцией антителом к рецептору ИЛ-2 [22,23]. Дальнейшие исследования использования мезенхимальных стволовых клеток, ксенотрансплантации и достижений в регенеративной медицине должны привести к лучшим результатам у реципиентов трансплантата за счет повышения толерантности, избегая или минимизируя использование иммуносупрессивной терапии [23].…”

Section: поддерживающая иммуносупрессияunclassified

General Principles of Modern Immunosuppressive Therapy

Nykonenko¹

2021

Transplant. artif. organs

View full text Add to dashboard Cite

Immunosuppressive therapy is the most important component of drug treatment after organ transplantation. The goal of immunosuppression is to prevent acute and chronic rejection while maximizing patient survival, and long-term graft survival remains a major therapeutic challenge before and after organ transplantation. However, the benefits of immunosuppressive therapy must be balanced against the side effects and underlying toxicity of the drugs used.Immunosuppressants can be classified as induction agents, maintenance therapy, treatment of acute rejection and chronic rejection, and antibody directed therapy. Although induction therapy remains a subject of debate in the field of organ transplantation, it is still used in most transplant centers. Protocols for maintenance immunosuppressive therapy are more or less standardized and include, as a rule, three drugs, a calcineurin inhibitor, an antimetabolite, and a glucocorticoid. The presence of HLA antibodies in transplantation candidates and the development of de novo antibodies after transplantation remain a serious therapeutic problem before and after organ transplantation. In this lecture, we will look at the drugs used to induce and maintain immunosuppression, as well as their effectiveness in preventing side effects.

show abstract

“…In KT, then, new biomarker molecules are clearly needed for early determination and post-transplant success [ 5 , 13 , 14 , 15 , 16 ]. Ideally, a biomarker should be non-invasive, reliable to monitor, appear early during injury onset, and correlate with the degree of injury [ 17 ]. Many studies have investigated proteomic techniques as potential molecular markers discriminating among or predicting allograft outcomes.…”

Section: Introductionmentioning

confidence: 99%

Biomarker-Development Proteomics in Kidney Transplantation: An Updated Review

Sirolli

Piscitani

Bonomini

2023

IJMS

View full text Add to dashboard Cite

Kidney transplantation (KT) is the optimal therapeutic strategy for patients with end-stage renal disease. The key to post-transplantation management is careful surveillance of allograft function. Kidney injury may occur from several different causes that require different patient management approaches. However, routine clinical monitoring has several limitations and detects alterations only at a later stage of graft damage. Accurate new noninvasive biomarker molecules are clearly needed for continuous monitoring after KT in the hope that early diagnosis of allograft dysfunction will lead to an improvement in the clinical outcome. The advent of “omics sciences”, and in particular of proteomic technologies, has revolutionized medical research. Proteomic technologies allow us to achieve the identification, quantification, and functional characterization of proteins/peptides in biological samples such as urine or blood through supervised or targeted analysis. Many studies have investigated proteomic techniques as potential molecular markers discriminating among or predicting allograft outcomes. Proteomic studies in KT have explored the whole transplant process: donor, organ procurement, preservation, and posttransplant surgery. The current article reviews the most recent findings on proteomic studies in the setting of renal transplantation in order to better understand the effective potential of this new diagnostic approach.

show abstract

Emerging monitoring technologies in kidney transplantation

Cited by 5 publications

References 78 publications

New Insights from Metabolomics in Pediatric Renal Diseases

New Insights from Metabolomics in Pediatric Renal Diseases

General Principles of Modern Immunosuppressive Therapy

Biomarker-Development Proteomics in Kidney Transplantation: An Updated Review

Contact Info

Product

Resources

About